Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: Long-term experience of a single centre.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
29
10
2020
accepted:
01
02
2021
pubmed:
5
2
2021
medline:
19
5
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
Scleroderma renal crisis (SRC) is a rare but one of the most recognised complications of systemic sclerosis (SSc). Corticosteroid (CS) use has been considered as a major risk factor for SRC. Several studies reported the efficacy of rituximab (RTX) with an acceptable safety profile in SSc. However, data on the long-term effect of high-dose CS concomitant to RTX on kidney function are lacking. We retrospectively analysed SSc patients (n = 35) treated with a lower dosage and short-interval RTX and concomitant high-dose CS at the Department of Internal Medicine at the Medical University of Graz between 2010 and 2019. The kidney function was assessed using the estimated glomerular filtration rate (eGFR) at every RTX admission. The annual decline of kidney function was evaluated by linear mixed model analysis. At the RTX initiation, one patient had a decreased kidney function indicated by eGFR < 60 mL/min/1.73 m A regular, high-dose CS given contemporary to RTX seems to be a safe option for kidney function in patients with SSc. Our findings provide additional knowledge in risk evaluation and planning of individualised therapies or designing clinical studies using RTX.
Identifiants
pubmed: 33540483
doi: 10.1111/ijcp.14069
pmc: PMC8243981
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14069Informations de copyright
© 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.
Références
Rheumatology (Oxford). 2018 Dec 1;57(12):2106-2113
pubmed: 30053212
Int J Clin Pract. 2021 Jun;75(6):e14069
pubmed: 33540483
Arthritis Res Ther. 2020 Mar 24;22(1):59
pubmed: 32209135
Clin Exp Dermatol. 2015 Mar;40(2):211-2
pubmed: 25250643
Am J Kidney Dis. 2019 Feb;73(2):184-193
pubmed: 30122544
Ann Rheum Dis. 2015 Jun;74(6):1188-94
pubmed: 24442885
BMC Nephrol. 2019 Jul 25;20(1):279
pubmed: 31345158
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Rheumatology (Oxford). 2020 Dec 1;59(12):3731-3736
pubmed: 32413118
Arthritis Rheumatol. 2018 Nov;70(11):1820-1828
pubmed: 29781586
Am J Kidney Dis. 2016 May;67(5):728-41
pubmed: 26597926
Autoimmun Rev. 2019 Dec;18(12):102403
pubmed: 31639515
Ann Rheum Dis. 2019 Jul;78(7):979-987
pubmed: 30967395
BMJ Case Rep. 2014 Nov 13;2014:
pubmed: 25395468
Nat Rev Nephrol. 2016 Nov;12(11):678-691
pubmed: 27641135
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Trials. 2018 Aug 22;19(1):449
pubmed: 30134971
Arthritis Rheum. 1998 Sep;41(9):1613-9
pubmed: 9751093
Ann Rheum Dis. 2017 Aug;76(8):1327-1339
pubmed: 27941129
Rheumatol Int. 2013 Sep;33(9):2225-30
pubmed: 23446441